All In Biotech

Drug Trial Radar · NCT07033026

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia

Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

136

Planned (sponsor's estimate)

Start

Jun 25, 2025

Primary completion

Apr 2027

Study completion Dec 2027

Sponsor

Lead sponsor
NGM Biopharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Jun 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

Conditions

  • Colorectal Cancer
  • CRC (Colorectal Cancer)
  • Cancer Cachexia

Interventions

  • NGM120 Q4WDrug

    NGM120 given subcutaneously every 4 weeks

  • NGM120 Q8WDrug

    NGM120 given subcutaneously every 8 weeks

  • Placebo givenDrug

    Placebo given subcutaneously every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in body weight at Week 12Time frame: 12 Weeks
  2. Treatment-emergent adverse events (TEAEs) characterized by type, frequency, severity, timing, seriousness, and relationship to study drugTime frame: 44 Weeks

Locations

28 sites in 4 countries. Site status is shown where the registry gives one.

  • NGM Clinical Study Site

    Los Angeles, California · Recruiting

  • NGM Clinical Study Site

    Los Angeles, California · Recruiting

  • NGM Clinical Study Site

    Santa Rosa, California · Recruiting

  • NGM Clinical Study Site

    Margate, Florida · Recruiting

  • NGM Clinical Study Site

    Baltimore, Maryland · Recruiting

  • NGM Clinical Study Site

    New York, New York · Recruiting

  • NGM Clinical Study Site

    Toledo, Ohio · Recruiting

  • NGM Clinical Study Site

    Youngstown, Ohio · Recruiting

  • NGM Clinical Study Site

    Dallas, Texas · Recruiting

  • NGM Clinical Study Site

    Kingwood, Texas · Withdrawn

  • NGM Clinical Study Site

    Laredo, Texas · Recruiting

  • NGM Clinical Study Site

    Richmond, Virginia · Recruiting

  • NGM Clinical Study Site

    Appleton, Wisconsin · Recruiting

  • NGM Clinical Study Site

    Tbilisi, Georgia · Recruiting

  • NGM Clinical Study Site

    Tbilisi, Georgia · Recruiting

  • NGM Clinical Study Site

    Tbilisi, Georgia · Recruiting

  • NGM Clinical Study Site

    Tbilisi, Georgia · Recruiting

  • NGM Clinical Study Site

    Tbilisi, Georgia · Recruiting

  • NGM Clinical Study Site

    Goyang, South Korea · Recruiting

  • NGM Clinical Study Site

    Goyang, South Korea · Recruiting

  • NGM Clinical Study Site

    Incheon, South Korea · Recruiting

  • NGM Clinical Study Site

    Seoul, South Korea · Recruiting

  • NGM Clinical Study Site

    Seoul, South Korea · Recruiting

  • NGM Clinical Study Site

    Seoul, South Korea · Recruiting

  • NGM Clinical Study Site

    Suwon, South Korea · Recruiting

  • NGM Clinical Study Site

    Taichung, Taiwan · Recruiting

  • NGM Clinical Study Site

    Taipei, Taiwan · Recruiting

  • NGM Clinical Study Site

    Taoyuan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.